State officials in Massachusetts are seeking to permanently shut down the Framingham drug compounding facility that is the source of the contaminated steroid that’s sickened more than 300 people across the country with fungal meningitis. The outbreak that’s now killed 23 people nationwide has put a spotlight on drug compounding industry- which has not been regulated closely by the FDA in recent years.
On Boston Public Radio, Emily Rooney talks with Sarah Sellers, a licensed pharmacist and epidemiologist who has worked in compounding pharmacies. Sellers is a former compliance officer for the FDA, and now works as a private consultant. In 2003, she testified before Congress about her concerns with drug compounding facilities.